Replimune Group, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 17.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.67B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Details
| Name | Replimune Group, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 465 |
| Founded | 2015 |
| Ipo Date | 2018-07-20 |
| Ceo | Sushil Patel |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| Isin | US76029N1063 |
| Cusip | 76029N106 |
| Cik | 0001737953 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Sushil Patel Ph.D. | Chief Executive Officer and Director |
| Emily Luisa Hill | Chief Financial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Philip Astley-Sparke F.S.A. | Executive Chairman |
| Carolyn Trott | Senior Vice President of Quality Assurance |
| Kari Jeschke | Senior Vice President of Regulatory Affairs |
| Michelle DiNapoli | Chief Commercial Officer |
Contact
| Address | 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, Massachusetts 01801, United States |
| Phone | 781 222 9600 |
| Website | https://www.replimune.com |